Thanks for all parts of your post, Rhonda.
Is the comment at the beginning of the article true?
"Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer."
The article says the samples they used were exposed to both trastuzumab and another chemo. So would the result be the same if they had only used trastuzumab and not the other chemo? In other words, do the markers geuinely ID the subtypes that are resistant to Herceptin, PERIOD, or do they ID the subtypes that are resistant if the tissue is exposed to the other chemo or the other chemo plus trastuzumab?
AlaskaAngel
|
Threaded Mode